Prestige Consumer Healthcare (NYSE:PBH) Hits New 12-Month Low – Here’s Why

Prestige Consumer Healthcare Inc. (NYSE:PBH) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $55.27 and last traded at $54.8020, with a volume of 53794 shares traded. The stock had previously closed at $57.68.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Jefferies Financial Group lowered their target price on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $76.50.

Prestige Consumer Healthcare Stock Down 5.1%

The company has a market cap of $2.59 billion, a price-to-earnings ratio of 14.43, a P/E/G ratio of 1.86 and a beta of 0.47. The stock’s 50-day moving average is $64.99 and its 200-day moving average is $62.99. The company has a current ratio of 3.11, a quick ratio of 1.93 and a debt-to-equity ratio of 0.58.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company had revenue of $283.44 million during the quarter, compared to analyst estimates of $286.93 million. During the same quarter in the previous year, the business posted $1.22 earnings per share. The company’s revenue for the quarter was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the sale, the vice president directly owned 41,048 shares of the company’s stock, valued at $2,706,294.64. The trade was a 2.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of hedge funds have recently added to or reduced their stakes in PBH. Hsbc Holdings PLC increased its holdings in shares of Prestige Consumer Healthcare by 23.1% during the fourth quarter. Hsbc Holdings PLC now owns 24,867 shares of the company’s stock valued at $1,528,000 after acquiring an additional 4,660 shares in the last quarter. Rockefeller Capital Management L.P. grew its position in Prestige Consumer Healthcare by 35.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 2,712 shares of the company’s stock valued at $167,000 after purchasing an additional 710 shares during the period. Caitong International Asset Management Co. Ltd grew its position in Prestige Consumer Healthcare by 69.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after purchasing an additional 236 shares during the period. Dean Capital Management bought a new stake in Prestige Consumer Healthcare during the 4th quarter valued at $2,523,000. Finally, Invesco Ltd. increased its stake in Prestige Consumer Healthcare by 7.5% during the 4th quarter. Invesco Ltd. now owns 584,021 shares of the company’s stock valued at $36,028,000 after purchasing an additional 40,950 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).